Aug. 4 at 11:05 AM
$BNTX Throughout his career, Uğur Şahin co-founded Ganymed Pharmaceuticals, BioNTech, and the research organizations TRON and Ci3.
Looking at his track record excluding COVID-19, a clear pattern emerges:
• TRON and Ci3 were research organizations funded primarily through government grants, research funding, and scientific collaborations, not commercial product sales.
• Ganymed Pharmaceuticals developed promising oncology drug candidates but did not commercialize an approved medicine before its acquisition by Astellas Pharma in 2016. Its lead asset continued development under Astellas.
• BioNTech, prior to COVID-19, had no commercially approved products. Its revenues came mainly from research partnerships, licensing agreements, grants, and external funding while advancing its oncology pipeline.
Excluding the COVID-19 vaccine, the organizations Şahin co-founded relied largely on funding, grants, and strategic partnerships rather than sustained revenue from marketed products.
